These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19887957)

  • 41. Possible link between history of hypersensitivity to a specific non-steroidal anti-inflammatory drug (NSAID) and positive results following challenge test to alternative NSAIDS.
    Trombetta D; Imbesi S; Vita G; Isola S; Minciullo PL; Saija A; Gangemi S
    Arzneimittelforschung; 2009; 59(8):410-4. PubMed ID: 19813464
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.
    Andersohn F; Suissa S; Garbe E
    Circulation; 2006 Apr; 113(16):1950-7. PubMed ID: 16618816
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gastrointestinal safety of coxibs: systematic review and meta-analysis of observational studies on selective inhibitors of cyclo-oxygenase 2.
    Martín Arias LH; Martín González A; Sanz Fadrique R; Salgueiro Vázquez E
    Fundam Clin Pharmacol; 2019 Apr; 33(2):134-147. PubMed ID: 30383903
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
    Tannenbaum H; Bombardier C; Davis P; Russell AS;
    J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatotoxicity induced by coxibs: how concerned should we be?
    Bessone F; Hernandez N; Roma MG; Ridruejo E; Mendizabal M; Medina-Cáliz I; Robles-Díaz M; Lucena MI; Andrade RJ
    Expert Opin Drug Saf; 2016 Nov; 15(11):1463-1475. PubMed ID: 27537326
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of nonsteroidal anti-inflammatory drugs on blood pressure, with an emphasis on newer agents.
    Armstrong EP; Malone DC
    Clin Ther; 2003 Jan; 25(1):1-18. PubMed ID: 12637109
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The coxibs and traditional nonsteroidal anti-inflammatory drugs: a current perspective on cardiovascular risks.
    Cairns JA
    Can J Cardiol; 2007 Feb; 23(2):125-31. PubMed ID: 17311118
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Defects in mouse nephrogenesis induced by selective and non-selective cyclooxygenase-2 inhibitors.
    Olliges A; Wimmer S; Nüsing RM
    Br J Pharmacol; 2011 Jul; 163(5):927-36. PubMed ID: 21391980
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiovascular risk, hypertension, and NSAIDs.
    White WB
    Curr Rheumatol Rep; 2007 Apr; 9(1):36-43. PubMed ID: 17437665
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [What do we know about the cardiovascular toxicity of the NSAIDs?].
    Sibilia J; Deray G; Montalescot G
    Presse Med; 2006 Sep; 35 Suppl 1():11-23. PubMed ID: 17870549
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges.
    Patrono C; Baigent C
    Mol Interv; 2009 Feb; 9(1):31-9. PubMed ID: 19299662
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The cardiovascular safety of celecoxib.
    Liew D; Krum H
    Future Cardiol; 2005 Nov; 1(6):709-22. PubMed ID: 19804045
    [TBL] [Abstract][Full Text] [Related]  

  • 53. NSAIDs and increased blood pressure. What is the clinical significance?
    Johnson AG
    Drug Saf; 1997 Nov; 17(5):277-89. PubMed ID: 9391772
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac.
    Walker C
    Int J Rheumatol; 2018; 2018():1302835. PubMed ID: 30631366
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A cohort study to evaluate cardiovascular risk of selective and nonselective cyclooxygenase inhibitors (COX-Is) in arthritic patients attending orthopedic department of a tertiary care hospital.
    Bhosale UA; Quraishi N; Yegnanarayan R; Devasthale D
    Niger Med J; 2014 Sep; 55(5):417-22. PubMed ID: 25298608
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nonsteroidal anti-inflammatory drugs and hypertension. The risks in perspective.
    de Leeuw PW
    Drugs; 1996 Feb; 51(2):179-87. PubMed ID: 8808162
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prostaglandins: modulators of inflammation and cardiovascular risk.
    Fitzgerald GA
    J Clin Rheumatol; 2004 Jun; 10(3 Suppl):S12-7. PubMed ID: 17043495
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Blood pressure effects of COX-2 inhibitors.
    Krum H; Aw TJ; Liew D; Haas S
    J Cardiovasc Pharmacol; 2006; 47 Suppl 1():S43-8. PubMed ID: 16785828
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing.
    El-Malah AA; Gineinah MM; Deb PK; Khayyat AN; Bansal M; Venugopala KN; Aljahdali AS
    Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890126
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Traditional NSAIDs and coxibs: is one better than the other?
    Mukherjee D
    Eur Heart J; 2017 Jun; 38(23):1851-1852. PubMed ID: 28329068
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.